Tech Company Financing Transactions
Tenaya Therapeutics Funding Round
Tenaya Therapeutics, operating out of San Francisco, raised $92 million in funding from Casdin Capital, GV and The Column Group.
Transaction Overview
Company Name
Announced On
10/4/2019
Transaction Type
Venture Equity
Amount
$92,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance and to expand Tenaya's pipeline and to strengthen the science, capabilities, and intellectual property that provide the foundation for Tenaya's multi-modality product platforms -- Cellular Regeneration, Gene Therapy, and Precision Medicine.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
171 Oyster Point Blvd. 500
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Tenaya Therapeutics is a biopharmaceutical company with a mission to discover, develop, and deliver potentially curative treatments that target the underlying causes of heart disease. Tenaya is advancing multiple candidates from three product platforms -- Cellular Regeneration, Gene Therapy, and Precision Medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Faraz Ali
Chief Medical Officer
Whit Tingley
Chief Scientific Officer
Timothy Hoey
Vice President
Jay Vora
VP - Manufacturing
Kee-Hong Kim
Browse more venture capital transactions:
Prev: 10/4/2019: Accel Robotics venture capital transaction
Next: 10/4/2019: Aeovian Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs